Blood test to predict immunotherapy benefit in advanced cancer
Treatments studied
Part of Cancer, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial is testing a simple blood test (using white blood cells) to see if it can predict how well immunotherapy will work for people with advanced cancer. If you are starting immunotherapy soon as your first treatment, this study might help guide your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been newly diagnosed with advanced (spread) cancer of one of these types: non-small cell lung cancer, melanoma (skin cancer), head and neck cancer, kidney cancer, or triple-negative breast cancer.
- You must be about to receive immunotherapy as your first treatment. This may be alone or combined with other drugs like chemotherapy.
- You must be at least 18 years old.
- You must be in reasonably good health. That means your blood cell counts, kidney function, and liver function are within normal limits (your doctor can test this).
- You must not have any other active cancer that has required treatment in the past 2 years.
- For lung cancer patients, you must not have certain genetic mutations (like EGFR or ALK) that have an approved targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a simple blood test to see if it can predict how well your cancer will respond to immunotherapy. You will give blood samples before and during treatment, and the researchers will analyze small particles in your blood to find clues about your likely response.
This study looks at using a blood test that detects tiny pieces of cancer DNA (called ctDNA) to help decide how long patients with advanced melanoma should stay on immunotherapy. It may help some patients safely stop treatment earlier if the blood test shows the cancer is under control.
This trial is for people with advanced non-small cell lung cancer (NSCLC) who have not yet started treatment. It studies a simple blood test that checks for genetic changes in the cancer, to help doctors choose the most effective first treatment.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This trial tests whether a “liquid biopsy” blood test can help predict how well first immunotherapy will work for people with stage IV lung cancer. It may help doctors choose the most effective treatment strategy sooner.
This trial studies a simple blood test that may predict how well your body responds to chemotherapy plus immunotherapy before surgery for triple-negative breast cancer. The goal is to use these clues to personalize your treatment in the future.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.